Ascelia Pharma to present at Avanza börsdag, 22 May 2019

2019-05-20
Download
On 22 May 2019, Ascelia Pharma’s CEO Magnus Corfitzen will present at the Avanza share seminar (“börsdag”). The presentation will be held at Operaterassen in Stockholm. Ascelia Pharma’s presentation starts at 9:45am CET and will also be broadcasted live as a webcast: https://tv.streamfabriken.com/2019-05-22-ascelia-pharma

To register for the seminar, please visit: https://financialhearings.com/event/11336

The presentation will also be available on Ascelia Pharma’s website after the seminar via the links found above.

For more information, please contact
Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 4.00pm CET on 20 May 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

2021-05-12

Quarterly Report Q1 2021: US office opened in preparation of launch

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q1 2021 (January – March 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations
2021-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Today, on 5 May 2021, the annual general meeting was held in Ascelia Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
2021-04-30

Number of shares and votes in Ascelia Pharma AB